key: cord-0952437-5bmtqp07 authors: Kennalley, A. L.; Furst, J. A.; Mynarski, N. J.; McCall, K. L.; Piper, B. J. title: Methadone Distribution Increased from 2010 to 2019 for Opioid Use Disorder Treatment in the US date: 2022-03-12 journal: nan DOI: 10.1101/2022.03.09.22272154 sha: 6f4e34aae8d4ce57aa677c6076c2f5956481130e doc_id: 952437 cord_uid: 5bmtqp07 Objectives: To identify US prescription trends in methadone distribution for OUD from 2010 to 2020. Methods: The weight of methadone in grams distributed to OTPs per state was derived from the US Drug Enforcement Administration's Automated Reports and Consolidated Ordering System. Methadone was adjusted for state population and compared across all fifty states and Washington DC from 2010 to 2020. Results: The overall distribution of methadone to OTPs significantly (P < 0.0001) increased from 2010 to 2019 (+61.0%) and from 2015 to 2020 (+26.22%). The states with the highest percent change from 2010 to 2020 were Montana (+897.02%), Alaska (+421.11%), and Vermont (+353.67%). In contrast with prior increase of distribution, from 2019 (pre-COVID-19 pandemic) to 2020 (during pandemic), there was no significant change in the distribution of methadone to OTPs (-0.09%). Ohio (+26.02%) significantly increased while Alabama (-21.96%), New Hampshire (-24.13%) and Florida (-28.97%) significantly decreased methadone relative to the national mean. Conclusions: This investigation revealed two trends related to methadone distribution in the US: increased utilization over the past decade and a plateau in utilization from 2019 to 2020. Policies are needed to remove access barriers to methadone treatment during the COVID-19 pandemic in order to reduce the worsening crisis of opioid overdoses in the US. The United States (US) Food and Drug Administration (FDA) has approved methadone, buprenorphine, and naltrexone as treatments for Opioid Use Disorder (OUD) (1) . Methadone is a long acting synthetic opioid used to treat OUD through maintenance therapy in opioid treatment programs (OTP) (1) (2) (3) . There have been several policy changes impacting OUD care during the COVID-19 pandemic. Methadone Take-Home doses have been expanded to 28 days for stable patients and 14 days for less stable patients, urine analyses requirements have been relaxed, and telemedicine has been expanded for established patients (4) (5) . However, unlike for buprenorphine, starting methadone required an in-person visit. Prior research supporting the use of methadone for OUD frequently required the administration of counseling in conjunction with methadone treatment, however, the pandemic has also led to the relaxation of these counseling requirements (6) . Methadone treatment, though efficacious for OUD, is not without serious adverse effects like all opioids. Studies show that pregnant mothers using methadone for OUD can cause fetal dependence and may alter the white matter of the newborn's brain (2) (7) (8) . An alternative to methadone, buprenorphine, has also raised safety concerns. For example, a recent FDA safety concern issued in January 2022 warned that the oral formulation has been associated with over 300 dental problems documented since its release in 2002 (9). In addition to adverse effects, a study conducted between 2004 and 2015 revealed that buprenorphine is widely unavailable to those who are neither wealthy nor white, with Black patients having a statistically reduced probability of receiving a prescription (10). Treatment with methadone, on the other hand, has been demonstrated to be superior to buprenorphine in reducing criminal activity, HIV infection, hepatitis, and mortality (2)(11-14). Additionally, a Cochrane Review concluded that methadone was superior to buprenorphine in retaining patients in treatment (15) . There have been over one-million drug overdoses in the US since the start of the opioid epidemic (16) . The COVID-19 pandemic has placed tremendous stress on the health care system including the delivery of OUD treatments. Moreover, from April 2020 to April 2021, the number of drug overdoses in the United States exceeded onehundred thousand, a +28.5% increase over the previous year (17) . With a 60% rise in overdoses compared to the previous year, May 2020 has been the deadliest month in record (18) . These massive increases in overdoses point to a failure in treating patients for OUD during the COVID-19 pandemic. A cross-sectional study, conducted from May to June 2020 in the US and Canada, identified a barrier to opioid treatment during the COVID-19 pandemic due to methadone clinics not accepting new patients in over 10% of clinics. Most importantly, new patients wishing to initiate methadone treatment were faced with this barrier in 20% of clinics (19) . Similarly, prior to the pandemic, both methadone and buprenorphine-based OTPs were found to be effective in US jails and prisons; however, following the pandemic, these OTPs have been discontinued (20) (21) . Together, it is very important to examine the changes in methadone distribution during the COVID-19 pandemic and determine whether there are regional disparities in access to this evidence-based pharmacotherapy. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The distribution amounts of methadone (in grams) were obtained from the Drug Enforcement Administration's (DEA) Automated Reports and Consolidated Ordering System (ARCOS) yearly drug summary reports for the years 2010, 2015, 2019 and 2020. ARCOS is a federal program mandated by the 1970 Controlled Substances Act to track the distribution of DEA controlled substances from the following-pharmacies, hospitals, practitioners, teaching institutions, mid-level practitioners, and OTPs. Previous pharmacoepidemiologic studies have utilized the ARCOS database (22) (23) (24) . Methadone prescriptions distributed to OTPs were classified as an OUD treatment. The was unavailable when data-analysis was completed (2/2022), estimated distribution was determined by doubling the values for the first two-quarters. This study was approved by the institutional review boards of the University of New England and Geisinger. The percent change of methadone distribution for OUD was compared between states for time spans of ten years, five years and one year respectively. The distribution methadone, corrected for population, compared between years-2010 and 2020, 2015 and 2020, and 2019 and 2020 were considered significant if the t-test indicated P < All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Examination of 2015 relative to 2020 revealed the national average methadone distribution for OUD increased by +26.22% (SD=50.38%), with thirty-eight states increasing and eleven states decreasing. A t-test again revealed a significant (P < 0.0001) increase. There were significant increases (P < 0.05) in Alaska (+135.34%) and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2022. ; https://doi.org/10.1101/2022.03.09.22272154 doi: medRxiv preprint Mississippi (+311.48%) relative to the national mean ( Figure 2 ). However, from 2019 to 2020 (i.e., pre-to post-COVID-19 pandemic), the distribution of methadone was stable (-0.091%, SD = 10.81%). Slightly over half (twenty-eight) of states showed an increase and twenty-two states exhibited a decrease. A t-test indicated there was no significant (P = 0.76) difference between 2019 and 2020. Examination of specific states revealed an increase in Kentucky (+18.68%) and a significant increase (P < 0.05) in Ohio (+26.02%) relative to the national mean. There were appreciable decreases in Nebraska (-16.6%), South Dakota (-17.27%), and Mississippi (-20.53%), and significant decreases (P < 0.05) in Alabama (-21.96%), New Hampshire (-24.13%) and Florida (-28.97%) relative to the national mean ( Figure 3 ). Provisional analysis revealed that distribution in 2021 was 4.9% lower than 2019 and 5.0% lower than 2020 (Supplemental Figure 1A ). The average methadone distribution in the US for OUD was 46.03 mg/person (SD 35.47) in 2020. There was significantly more (P < 0.05) distributed in Vermont However, nine states had fewer OTPs in 2020 relative to 2015 or 2010 (Arkansas, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 5 ). The key finding of this study was that the pronounced and significant increase in methadone distribution to OTPs for OUD over the past decade has reversed with a nonsignificant decrease (-0.09%) from 2019 to 2020 (24) . Preliminary analysis reveals further declines (5%) in 2021. Following this trend, there were also significant increases in the number of OTPs per one million persons per state from 2010 to 2020. These findings point to the overwhelming prevalence of OUD in the US and the necessity for more OTPs to combat the escalating problem. Eight states showed a reduction in OTPs from 2015 to 2020 (Vermont, Maine, Kansas, Minnesota, Hawaii, Arkansas, Nebraska, and South Dakota) which could be due to funding or policies for OTPs in the state. Looking at how the COVID-19 pandemic affected OUD from 2019 to 2020, it appears methadone distribution to OTPs did not increase significantly. Poison control reports involving intentional methadone exposure showed a subtle (+5%) but significant, increase during this period (27) . In addition, the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) reported that drug overdose mortality increased by +31% between 2019 and 2020. However, the rate of methadone overdose deaths remained low with no significant increase suggesting no change in methadone misuse during the COVID-19 pandemic (28) . During the ongoing COVID-19 pandemic, this highlights the importance of methadone treatment, as well as safe storage, and the need for increased availability to prevent opioid overdoses. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This study reveals the importance of policy change as it is apparent there is an excessive need for more access to OUD therapy, specifically methadone treatment, in the US. The Pew Report states that over 400,000 people in the US received methadone from an OTP pre-pandemic (2019) with over 90% located in urban areas, making it challenging for rural patients to make the daily trip to receive their medication (29) . In March 2020, SAMHSA released guidelines allowing the regulatory authorities of all states to request blanket exceptions to allow OTP patients to take home doses of methadone and buprenorphine (30) . These guidelines were extended in November 2021, and many providers and public health researchers are calling for these take home dosage rules to be continued post-pandemic (31) (32) . The number of pharmacies which distributed buprenorphine was 34-fold greater in 2021 than the OTPs that distributed methadone. It is currently curious that there are more restrictions in the US for prescribing methadone than for other Schedule II substances like fentanyl or oxycodone. Overcoming the "Not in my Backyard" (NIMBY) stigma surrounding OTPs is not a trivial undertaking (33) . There is no shortage of strategies to bring the US more inline with other Western countries like supervised administration in pharmacies, primary care providers, or with mobile units (13) (19) (34) . The strengths of this report include novel and timely data from ARCOS which is comprehensive for both distribution and number of distributors. Potential caveats and limitations stem from the fact that methadone distribution is reported in ARCOS by weight rather than prescriptions. Importantly, other pharmacoepidemiological research that compared another Schedule II substance from ARCOS to a state Prescription Drug Monitoring Program identified a high correspondence (r = +.985) (22) . The infrequency All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (200 km2) is an important finding. However, prior research found that another rural state, Maine, which ranked tenth in the US, had three-OTPs in a single thirty-thousand-person city (Bangor) and none in other areas in northern Maine (35). The non-homogenous distribution within states should also be a concern for policy makers. Future research should also be focused on determining which patient In conclusion, this study identified a reversal over the past-decade in the distribution of methadone for OUD in the US. The pronounced geographical disparities, particularly in rural and western states in OTP is a long-standing concern. The many policy accommodations to COVID-19 may present an important opportunity to determine which factors most impact the accessibility, adherence, and efficacy of methadone. Thank you to Iris Johnston for providing access to journal articles. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. WHO Essential Medication C yes yes All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder Use of Methadone Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity Medicare Program; Opioid Treatment Programs: CY 2022 Methadone Payment Exception Methadone Maintenance Therapy Versus No Opioid Replacement Therapy for Opioid Dependence Prenatal Methadone Exposure is Associated with Altered Neonatal Brain Development Trends and Disparities in Receipt of Pharmacotherapy Among Pregnant Women in Publically All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Buprenorphine Maintenance Versus Placebo or Methadone Maintenance for Opioid Dependence Vital Statistics Rapid Release -Provisional Drug Overdose Data Drug Overdose Deaths in the U.S. Top 100,000 Annually COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States Methadone Access for Opioid Use Disorder during the COVID-19 Pandemic within the United States and Canada Methadone and Buprenorphine Treatment in United States Jails and Prisons: Lessons From Early Adopters Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons Trends in Medical Use of Opioids in the Declining National Codeine Distribution in United States Hospitals and Pharmacies Pronounced Regional Disparities in United States Methadone Distribution Opioid Distribution Trends (2006-2017) in the US Territories Methadone Exposures Reported to Poison Control Centers in the United States Following the COVID-19-Related Loosening of Federal Methadone Regulations Drug Overdose Deaths in the United States All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Methadone Take-Home Flexibilities Extension Guidance The Impact of Relaxation of Methadone Take-Home Protocols on Treatment Outcomes in the COVID-19 Era Extending Pandemic Flexibilities for Opioid Use Disorder Treatment: Unsupervised Use of Opioid Treatment Medications Socio-Spatial Stigmatization and the Contested Space of Addiction Treatment: Remapping Strategies of Opposition to the Disorder of Drugs Methadone on Wheels-A New Option to Expand Access to Care Through Mobile Units